Adults with young-onset Parkinsons disease may be born with malfunctioning brain cells, a new Cedars-Sinai study found with assistance from UCLA researchers.

This suggests factors other than environmental exposure likely contribute to neurodegenerative diseases such as Parkinsons.

Young-onset Parkinsons disease, a type of Parkinsons that develops before the age of 50, accounts for about 10% of all Parkinsons cases. Young-onset Parkinsons is a neurodegenerative disease, meaning it damages the central nervous system and results in a loss of proper motor function.

More than a million people are affected by this in the United States alone, said Zhan Shu, a postdoctoral scholar at the Semel Institute for Neuroscience and Human Behavior who participated in the Cedars-Sinai research.

To model the neurons involved in Parkinsons disease, the researchers used induced pluripotent stem cells, or iPSCs adult red blood cells that have been converted into stem cells that can give rise to any type of cell in the body. They converted iPSCs from individuals with young-onset Parkinsons disease into neurons that produce dopamine.

iPSC cells from patients with young-onset Parkinsons showed the signature changes seen in neurons in the brains of those with Parkinsons. Their findings were published in Nature Medicine in January.

Dopamine plays a large role in neural functions, and a lack of regulation of dopamine production causes many neurodegenerative diseases, Shu said. In individuals with Parkinsons disease, neurons that produce dopamine die off, which impairs motor regulation.

This will usually start with a tremor, Shu said. Its pretty obvious for family to see. Once you start to show symptoms, they move from the hands to the legs to the nonmotor parts as well.

The use of iPSCs allows researchers to determine how the disease progresses in absence of external environmental factors, said Alexander Laperle, a co-author of the study from Cedars-Sinai. iPSCs are important for this research because they simulate how diseased neurons form during human development.

Laperle compared the current research technique to a car crash. Researchers can see the impacts and physiology of the disease, however they cant see any of the development, similarly to how seeing a crashed car doesnt tell an observer how the crash occurred.

We dont know anything about how (neurodegenerative diseases) originated or progressed, he said. You cant directly observe this in a person.

Many of Parkinsons neurodegenerative symptoms occur many years before obvious symptoms can be detected, said Nigel Maidment, a professor at the Semel Institute who also participated in the research. Many of the symptoms are not as visible or obvious, Maidment said. Other symptoms can include cognitive issues, digestive tract issues and sleep disturbances.

There are many nonmotor symptoms that patients often describe as more distressing, Maidment said.

Detecting the presence of Parkinsons disease and malfunctioning neurons before major symptoms develop could assist researchers in potentially finding ways to slow or stop the diseases progression, Maidment added.

If we are to halt the progression of the disease it will be necessary to identify such changes early, Maidment said.

Many of the genetic causes of Parkinsons disease are still unknown. Laperle added that if any cases are genetic, it is likely that many genes interact to cause Parkinsons disease. The illness has no cure, but different treatment options can help individuals manage the symptoms.

Approximately 15% of Parkinsons disease patients have a family history of the illness, Shu said. It is still unclear how genetic causes contribute to the risk of developing the disease, he added.

Shu said the iPSC research at Cedars-Sinai will give researchers new models for drug development. He said he hopes to expand research territories beyond preclinical animal models.

Using human iPSCs instead of animal cells has the potential to make the search for treatment more effective, he added.

Thats the whole purpose of the paper, to find a platform for people to test (drugs), Shu said.

Many treatments that work in animal models cannot be translated to people, Laperle said. Part of this reason is because animals dont have neurodegenerative diseases the way humans do, he said.

If I give a drug to a mouse, I can have a positive impact on that animals symptoms, but its not a great predictor of when you give that drug to a person, he said.

Many of the drugs currently on the market only address the symptoms, Laperle said. For example, the drug levodopa helps replace missing dopamine in the central nervous system. However, patients can develop a tolerance to the drug and its efficacy eventually decreases.

Laperle said he hopes this research may allow for the development of more effective drugs that slow or stop the progression of this disease.

There arent any good approaches yet to slow this (progression) down or restore function, he said.

See the article here:
Study looks into how neurons function in adults with young-onset Parkinson's - Daily Bruin